Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for shares of ACADIA ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have earned a consensus rating of “Moderate Buy” from ...

We recently published a list of 12 Best Nasdaq Stocks Under $20 to Buy Now. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other best ...

Acadia Pharmaceuticals ACAD reported fourth-quarter 2024 earnings of 17 cents per share, missing the Zacks Consensus Estimate of 19 cents.The reported figure has been adjusted for the net proceeds ...

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United ...

Fireside Chat: Monday, April 7, 2025 at 10:15 a.m. Eastern Time Live webcasts of each fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an ...

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.28 per share a year ago.